Timothy J. Wilt

Timothy J. Wilt

Auto-generated profile, based on publicly available information

Timothy J. Wilt

Center for Care Delivery & Outcomes Research VA Health Care System Minneapolis Minnesota USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
TWTimothy J. Wilt
Timothy J. Wilt
MBMichael K. Brawer
Michael K. Brawer
KJKaren M. Jones
Karen M. Jones
MBMichael J. Barry
Michael J. Barry
WAWilliam J. Aronson
William J. Aronson
TWThomas Wheeler
Thomas Wheeler
The effectiveness of surgery versus observation for men with localized prostate cancer detected by means of prostate-specific antigen (PSA) testing is not known. From November 1994 through January 2002, we randomly assigned 731 men with localized prostate cancer (mean age, 67 years; median PSA value, 7.8 ng per milliliter) to radical prostatectomy or observation and followed them through January 2010. The primary outcome was all-cause mortality; the secondary outcome was prostate-cancer mortality. During the median follow-up of 10.0 years, 171 of 364 men (47.0%) assigned to radical prostatectomy died, as compared with 183 of 367 (49.9%) assigned to observation (hazard ratio, 0.88; 95% confidence interval [CI], 0.71 to 1.08; P=0.22; absolute risk reduction, 2.9 percentage points). Among men assigned to radical prostatectomy, 21 (5.8%) died from prostate cancer or treatment, as compared with 31 men (8.4%) assigned to observation (hazard ratio, 0.63; 95% CI, 0.36 to 1.09; P=0.09; absolute risk reduction, 2.6 percentage points). The effect of treatment on all-cause and prostate-cancer mortality did not differ according to age, race, coexisting conditions, self-reported performance status, or histologic features of the tumor. Radical prostatectomy was associated with reduced all-cause mortality among men with a PSA value greater than 10 ng per milliliter (P=0.04 for interaction) and possibly among those with intermediate-risk or high-risk tumors (P=0.07 for interaction). Adverse events within 30 days after surgery occurred in 21.4% of men, including one death. Among men with localized prostate cancer detected during the early era of PSA testing, radical prostatectomy did not significantly reduce all-cause or prostate-cancer mortality, as compared with observation, through at least 12 years of follow-up. Absolute differences were less than 3 percentage points. (Funded by the Department of Veterans Affairs Cooperative Studies Program and others; PIVOT ClinicalTrials.gov number, NCT00007644.)

13 July 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
TWTimothy J. Wilt
Timothy J. Wilt
KJKaren M. Jones
Karen M. Jones
MBMichael J. Barry
Michael J. Barry
GAGerald L. Andriole
Gerald L. Andriole
DCDaniel Culkin
Daniel Culkin
MBMichael K. Brawer
Michael K. Brawer
We previously found no significant differences in mortality between men who underwent surgery for localized prostate cancer and those who were treated with observation only. Uncertainty persists regarding nonfatal health outcomes and long-term mortality.

1 June 2020 in European Urology
Verified
Journal Article
Closed access
TWTimothy J. Wilt
Timothy J. Wilt
TVTien N. Vo
Tien N. Vo
LLLisa Langsetmo
Lisa Langsetmo
PDPhilipp Dahm
Philipp Dahm
TWThomas Wheeler
Thomas Wheeler
MBMichael K. Brawer
Michael K. Brawer

1 October 2014 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
BWBrittin Wagner
Brittin Wagner
GFGregory A. Filice
Gregory A. Filice
DDDimitri Drekonja
Dimitri Drekonja
NGNancy Greer
Nancy Greer
RMRoderick MacDonald
Roderick MacDonald
TWTimothy J. Wilt
Timothy J. Wilt
Objective: Evaluate the evidence for effects of inpatient antimicrobial stewardship programs (ASPs) on patient, prescribing, and microbial outcomes.Design: Systematic review.Methods: Search of MEDLINE (2000 through November 2013), Cochrane Library, and reference lists of relevant studies. We included English language studies with patient populations relevant to the United States (ie, infectious conditions and prescriptions required for antimicrobials) that evaluated ASP interventions and reported outcomes of interest. Study characteristics and outcomes data were extracted and reviewed by investigators and trained research personnel.Results: Few intervention types (eg, audit and feedback, guideline implementation, and decision support) substantially impacted patient outcomes, including mortality, length of stay, readmission, or incidence of Clostridium difficile infection. However, most interventions were not powered adequately to demonstrate impacts on patient outcomes. Most interventions were associated with improved prescribing patterns as measured by decreased antimicrobial use or increased appropriate use. Where reported, ASPs were generally associated with improvements in microbial outcomes, including institutional resistance patterns or resistance in the study population. Few data were provided on harms, sustainability, or key intervention components. Studies were typically of short duration, low in methodological quality, and varied in study design, populations enrolled, hospital setting, ASP intent, intervention composition and implementation, comparison group, and outcomes assessed.Conclusions: Numerous studies suggest that ASPs can improve prescribing and microbial outcomes. Strength of evidence was low, and most studies were not designed adequately to detect improvements in mortality or other patient outcomes, but obvious adverse effects on patient outcomes were not reported.

2 May 2012 in BJU International
Verified
Journal Article
Open access
PDF file
RMRoderick MacDonald
Roderick MacDonald
JTJames W. Tacklind
James W. Tacklind
IRIndulis Rutks
Indulis Rutks
TWTimothy J. Wilt
Timothy J. Wilt
What's known on the subject? and What does the study add? For the past 30 years Serenoa repens has become a widely used phytotherapy in the USA and in Europe, mostly because of positive comparisons to α‐blockers and 5α‐reductase inhibitors. During the last 4 years we have seen two very high quality trials comparing Serenoa repens to placebo and up to 72 weeks' duration. These trials found Serenoa repens no better than placebo, even (in one trial) at escalating doses. OBJECTIVE: To estimate the effectiveness and harms of Serenoa repens monotherapy in the treatment of lower urinary tract symptoms (LUTS) consistent with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and other sources through to January 2012 to identify randomised trials. Trials were eligible if they randomised men with symptomatic BPH to receive Serenoa repens extract monotherapy for at least 4 weeks in comparison with placebo, and assessed clinical outcomes and urodynamic measurements. Our primary outcome was improvement in LUTS, based on change in urological symptom‐scale scores. RESULTS: In all, 17 randomised controlled trials ( N = 2008) assessing Serenoa repens monotherapy (typically 320 mg/day) vs placebo met inclusion criteria, although only five reported American Urological Association Symptom Index (AUASI) or International Prostate Symptom Scores (IPSS). Trial lengths ranged from 4 to 72 weeks. The mean age of all enrolees was 64.3 years and most participants were of White race. The mean baseline total score was 14 points, indicating moderately severe symptoms. In all, 16 trials were double blinded and adequate treatment allocation concealment was reported in six trials. In a meta‐analysis of three high quality long‐to‐moderate term trials ( n = 661), Serenoa repens therapy was no better than placebo in reducing LUTS based on the AUASI/IPSS (weighted mean difference [WMD]−0.16 points, 95% confidence interval [CI]–1.45 to 1.14) or maximum urinary flow rate (Q max ; WMD 0.40 mL/s, 95% CI −0.30 to 1.09). Based on mostly short‐term studies, Q max measured at study endpoint were also not significantly different between treatment groups (WMD 1.15 mL/s, 95% CI −0.23 to 2.53) with evidence of substantial heterogeneity (I 2 58%). One long‐term dose escalation trial (72 weeks) found double and triple doses of Serenoa repens extract did not improve AUASI compared with placebo and the proportions of clinical responders (≥3 point decrease in the AUASI) were nearly identical (43% vs 44% for Serenoa repens and placebo, respectively) with a corresponding risk ratio of 0.96 (95% CI 0.76–1.22). Long‐term, Serenoa repens therapy was no better than placebo in improving nocturia in one high‐quality study ( P = 0.19). Pooled analysis of nine short‐term Permixon® trials showed a reduction in the frequency of nocturia (WMD −0.79 times/night, 95% CI–1.28 to −0.29), although there was evidence of heterogeneity (I 2 76%) Adverse events of Serenoa repens extracts were few and mild, and incidences were not statistically significantly different vs placebo. Study withdrawals occurred in ≈10% and did not differ between Serenoa repens and placebo. CONCLUSIONS: Serenoa repens therapy does not improve LUTS or Q max compared with placebo in men with BPH, even at double and triple the usual dose. Adverse events were generally mild and comparable to placebo.

6 July 2006 in Population Health Metrics
Verified
Journal Article
Open access
PDF file
MSMin-Woong Sohn
Min-Woong Sohn
HZHuiyuan Zhang
Huiyuan Zhang
NANoreen Arnold
Noreen Arnold
KSKevin Stroupe
Kevin Stroupe
BTBrent C Taylor
Brent C Taylor
DHDenise M Hynes
Denise M Hynes
Patient race in the Department of Veterans Affairs (VA) information system was previously recorded based on an administrative or clinical employee's observation. Since 2003, the VA started to collect self-reported race in compliance with a new federal guideline. We investigated the implications of this transition for using race/ethnicity data in multi-year trends in the VA and in other healthcare data systems that make the transition. All unique users of VA healthcare services with self-reported race/ethnicity data in 2004 were compared with their prior observer-recorded race/ethnicity data from 1997 – 2002 (N = 988,277). In 2004, only about 39% of all VA healthcare users reported race/ethnicity values other than "unknown" or "declined." Females reported race/ethnicity at a lower rate than males (27% vs. 40%; p < 0.001). Over 95% of observer-recorded data agreed with self-reported data. Compared with the patient self-reported data, the observer-recorded White and African American races were accurate for 98% (kappa = 0.89) and 94% (kappa = 0.93) individuals, respectively. Accuracy of observer-recorded races was much worse for other minority groups with kappa coefficients ranging between 0.38 for American Indian or Alaskan Natives and 0.79 for Hispanic Whites. When observer-recorded race/ethnicity values were reclassified into non-African American groups, they agreed with the self-reported data for 98% of all individuals (kappa = 0.93). For overall VA healthcare users, the agreement between observer-recorded and self-reported race/ethnicity was excellent and observer-recorded and self-reported data can be used together for multi-year trends without creating serious bias. However, this study also showed that observation was not a reliable method of race/ethnicity data collection for non-African American minorities and racial disparity might be underestimated if observer-recorded data are used due to systematic patterns of inaccurate race/ethnicity assignments.